20716786 18571250 36599005 21281685 23801826 29291394 15075741 21131478 19679875 18321937 19375355 19363136 15872060 22880017 22843703 16936262 21053743 15571597 23834689 35713937 32006823 16380550 15916982 18071089 22314145 22889676 22386586 2595451 - Search Results

Year	Number of Results
2002	1
2004	5
2005	5
2006	8
2007	6
2008	9
2009	14
2010	11
2011	14
2012	15
2013	9
2014	4
2015	5
2016	4
2017	10
2018	6
2019	2
2020	5
2021	4
2022	6
2023	1

1

Elangbam CS. Elangbam CS. Toxicol Pathol. 2010 Oct;38(6):837-48. doi: 10.1177/0192623310378027. Epub 2010 Aug 17. Toxicol Pathol. 2010. PMID: 20716786 Review.

2

Carcinoid heart disease.

Gustafsson BI, Hauso O, Drozdov I, Kidd M, Modlin IM. Gustafsson BI, et al. Int J Cardiol. 2008 Oct 13;129(3):318-24. doi: 10.1016/j.ijcard.2008.02.019. Epub 2008 Jun 20. Int J Cardiol. 2008. PMID: 18571250 Review.

3

Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation.

Castillero E, Fitzpatrick E, Keeney SJ, D'Angelo AM, Pressly BB, Simpson MT, Kurade M, Erwin WC, Moreno V, Camillo C, Shukla HJ, Inamdar VV, Aghali A, Grau JB, Salvati E, Nissim I, Rauova L, Oyama MA, Stachelek SJ, Brown C, Krieger AM, Levy RJ, Ferrari G. Castillero E, et al. Sci Transl Med. 2023 Jan 4;15(677):eadc9606. doi: 10.1126/scitranslmed.adc9606. Epub 2023 Jan 4. Sci Transl Med. 2023. PMID: 36599005

4

Aortic valve disease and treatment: the need for naturally engineered solutions.

Butcher JT, Mahler GJ, Hockaday LA. Butcher JT, et al. Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):242-68. doi: 10.1016/j.addr.2011.01.008. Epub 2011 Jan 31. Adv Drug Deliv Rev. 2011. PMID: 21281685 Review.

5

Transforming growth factor β1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study).

Elenkova A, Atanassova I, Kirilov G, Vasilev V, Kalinov K, Zacharieva S. Elenkova A, et al. Eur J Endocrinol. 2013 Jul 29;169(3):299-306. doi: 10.1530/EJE-13-0081. Print 2013 Sep. Eur J Endocrinol. 2013. PMID: 23801826

6

Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.

Driesbaugh KH, Branchetti E, Grau JB, Keeney SJ, Glass K, Oyama MA, Rioux N, Ayoub S, Sacks MS, Quackenbush J, Levy RJ, Ferrari G. Driesbaugh KH, et al. J Mol Cell Cardiol. 2018 Feb;115:94-103. doi: 10.1016/j.yjmcc.2017.12.014. Epub 2017 Dec 30. J Mol Cell Cardiol. 2018. PMID: 29291394 Free PMC article.

7

Angiogenic modulators in valve development and disease: does valvular disease recapitulate developmental signaling pathways?

Shworak NW. Shworak NW. Curr Opin Cardiol. 2004 Mar;19(2):140-6. doi: 10.1097/00001573-200403000-00013. Curr Opin Cardiol. 2004. PMID: 15075741 Review.

8

Role of the Rho pathway in regulating valvular interstitial cell phenotype and nodule formation.

Gu X, Masters KS. Gu X, et al. Am J Physiol Heart Circ Physiol. 2011 Feb;300(2):H448-58. doi: 10.1152/ajpheart.01178.2009. Epub 2010 Dec 3. Am J Physiol Heart Circ Physiol. 2011. PMID: 21131478 Free PMC article.

9

Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.

Connolly JM, Bakay MA, Fulmer JT, Gorman RC, Gorman JH 3rd, Oyama MA, Levy RJ. Connolly JM, et al. Am J Pathol. 2009 Sep;175(3):988-97. doi: 10.2353/ajpath.2009.081101. Epub 2009 Aug 13. Am J Pathol. 2009. PMID: 19679875 Free PMC article.

10

Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice.

Fabre A, Marchal-Sommé J, Marchand-Adam S, Quesnel C, Borie R, Dehoux M, Ruffié C, Callebert J, Launay JM, Hénin D, Soler P, Crestani B. Fabre A, et al. Eur Respir J. 2008 Aug;32(2):426-36. doi: 10.1183/09031936.00126907. Epub 2008 Mar 5. Eur Respir J. 2008. PMID: 18321937 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results